{
    "nctId": "NCT05885776",
    "briefTitle": "Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research",
    "officialTitle": "Preoperative Treatment of HR+/HER2+Breast Cancer With Pyrrolitinib Combined With Trastuzumab and AI Efficacy and Safety of: a Single Arm Multicenter Phase II Exploratory Study",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "Follow up on postoperative pathological reports for evaluation for Pathological complete response rate (tpCR: ypT0-is/ypN0)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female initial treatment patients aged \u2265 18 years and \u2264 75 years old\n* ECOG score 0-1\n* Stage II-IIIA invasive breast cancer, diameter \u2265 20mm\n* HER2 positive (IHC score of 3+, or 2+and ISH test positive)\n* ER\\>10%\n* Doctors choose to use letrozole/anastrozole for endocrine therapy\n* The definition of menopause includes any of the following: (Previous bilateral oophorectomy; Age)\u2265 60 years old; Age\\<60 years old and without chemotherapy, tamoxifen, toremifen, or ovarian suppressionUnder normal conditions, menopause lasts for \u2265 12 months, and follicle stimulating hormone (FSH) and estradiol are within the postmenopausal range;If receiving tamoxifen or toremifen and age\\<60 years, FSH and plasma estradiolWithin the postmenopausal range)\n* Left ventricular ejection fraction (LVEF) \u2265 50%\n* 12 lead electrocardiogram: QT interval (QTcF) corrected by Fridericia method for females\\<470ms\uff1b\n* The functional level of the main organs must meet the following requirements: blood routine: ANC \u2265 1.5 \u00d7 109/L\uff1b PLT\u226590 \u00d7 109/L\uff1b Hb\u226590 g/L\uff1bBlood biochemistry: TBIL \u2264 2.5 \u00d7 ULN\uff1b ALT and AST \u2264 2.5 \u00d7 ULN\uff1b BUN and Cr \u2264 1.5 \u00d7 ULN\uff1b\n* For female subjects who have not undergone menopause or surgical sterilization, during the treatment period and during the study treatment\n* Agree to abstain or use effective contraceptive methods for at least 2 months after the next administration; .Volunteer to join this study, sign informed consent, have good compliance, and be willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n* Stage IIIB-IV or inflammatory breast cancer\n* Metastatic tumor\n* Previous or concurrent malignant tumors, whose natural history or treatment may interfere with the safety of the research protocol Patients evaluated for sex or efficacy are not eligible to participate in this trial, but basal or squamous cell skin Except for cancer, cervical cancer in situ or bladder cancer, or the subject has no disease (other cancer) to survive At least 5 years.\n* Active infections that require systemic treatment\n* Has used any medication in this study within 14 days prior to enrollment\n* Major surgery (excluding biopsy) performed within 14 days before enrollment\n* Gastrointestinal dysfunction or diseases may seriously affect the absorption of drugs in this study (such as ulcerative Disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) or Severe damage to the ability to swallow capsules/tablets\n* Known history of myelodysplastic syndrome or acute myeloid leukemia\n* Have a history of abdominal fistula, gastrointestinal perforation, or abdominal abscess within 28 days\n* Have any history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months\n* Within 6 years, there is a history of acute coronary syndrome (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stent implantation) or symptomatic pericarditis",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}